G1 Therapeutics to stop cancer drug trial, shares fall 40%
(Reuters) – G1 Therapeutics Inc said on Monday it would end its cancer therapy study after a placebo outperformed the drug in its late-stage trial, sending its shares plunging as much as 40% before the opening bell. Although the drug, tralaciclib, achieved its target in the trial, preliminary anti-tumor efficacy data, including overall response rates …